CRISPR Therapeutics (NASDAQ:CRSP) Director Thomas Woiwode sold 222,258 shares of the company’s stock in a transaction on Friday, April 27th. The stock was sold at an average price of $50.11, for a total transaction of $11,137,348.38. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
CRSP stock traded up $4.05 during trading on Tuesday, hitting $56.78. The company had a trading volume of 2,631,100 shares, compared to its average volume of 1,174,590. CRISPR Therapeutics has a one year low of $54.08 and a one year high of $59.85. The stock has a market capitalization of $2.49 billion, a PE ratio of -34.11 and a beta of 3.58.
CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, May 9th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.05. The business had revenue of $1.36 million for the quarter, compared to analysts’ expectations of $3.64 million. CRISPR Therapeutics had a negative return on equity of 35.18% and a negative net margin of 189.60%. The firm’s revenue was down 49.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.54) earnings per share. sell-side analysts predict that CRISPR Therapeutics will post -2.6 earnings per share for the current year.
Several equities analysts recently commented on CRSP shares. Goldman Sachs began coverage on shares of CRISPR Therapeutics in a research note on Friday, April 6th. They set a “buy” rating and a $86.00 target price for the company. SunTrust Banks raised shares of CRISPR Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. BidaskClub lowered shares of CRISPR Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 24th. Zacks Investment Research upgraded shares of CRISPR Therapeutics from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Friday. Finally, Chardan Capital raised their target price on shares of CRISPR Therapeutics from $25.00 to $72.50 and gave the stock a “buy” rating in a report on Tuesday. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $64.28.
Several institutional investors have recently bought and sold shares of the business. Versant Venture Management LLC bought a new position in shares of CRISPR Therapeutics during the 1st quarter worth approximately $210,551,000. NEA Management Company LLC boosted its holdings in shares of CRISPR Therapeutics by 8.2% during the 1st quarter. NEA Management Company LLC now owns 3,484,464 shares of the company’s stock worth $159,275,000 after buying an additional 263,736 shares in the last quarter. Farallon Capital Management LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $20,160,000. Franklin Resources Inc. boosted its holdings in shares of CRISPR Therapeutics by 8.9% during the 4th quarter. Franklin Resources Inc. now owns 794,533 shares of the company’s stock worth $18,656,000 after buying an additional 65,200 shares in the last quarter. Finally, Global Thematic Partners LLC boosted its holdings in shares of CRISPR Therapeutics by 11.2% during the 4th quarter. Global Thematic Partners LLC now owns 633,452 shares of the company’s stock worth $14,873,000 after buying an additional 63,611 shares in the last quarter. Hedge funds and other institutional investors own 36.73% of the company’s stock.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.